Previously, only a few studies demonstrated the potential benefits of tesaglitazar, a dual PPARα/γ agonist, as an add-on therapy to metformin in patients with poorly controlled type 2 diabetes mellitus28. This evidence concerns the gene PPARA and type 2 diabetes mellitus.